ADAMA Reports Results for Third Quarter and First Nine Months of 2020
Strong business growth moderated by global currency weakness against the USD
Record Q3 Sales of $978 million, +12% at constant exchange rates (CER), +3% in USD
(RMB: +2%)
Driven by 11% volume growth, led by continued growth in emerging markets
Sales in US dollar terms impacted by an estimated $88 million due to weaker currencies
Record 9M Sales of $2,987 million, +8% in CER terms, +1% in USD (RMB: +3%)
Continued strong 8% volume growth despite ongoing global COVID-19 constraints
Sales in US dollar terms impacted by an estimated $222 million due to weaker currencies
Q3 EBITDA of $130 million (Q3’19: $144 million); impacted by estimated $71 million in
currency headwinds
Strong Q3 volume growth and reduced procurement costs more than offset by significant
currency weakness
Reduced operating expenses, despite inclusion of recent acquisitions
9M EBITDA of $436 million (9M’19: $509 million); impacted by estimated $164 million in
currency headwinds
Significant currency weakness more than offsetting continued volume growth, lower
procurement costs and reduction in operating expenses
Q3 Net Income of $21 million (Q3’19: $42 million); estimated FX impact of approximately
$81 million
Reflects lower operating income, higher financial expenses
9M Net Income of $95 million (9M’19: $173 million); estimated FX impact of approximately
$201 million
Reflects lower operating income, higher tax expenses due to BRL weakness in Q1
BEIJING, CHINA and TEL AVIV, ISRAEL, October 29, 2020 – ADAMA Ltd. (the “Company”)
(SZSE 000553), today reported its financial results for the third quarter and nine-month period
ended September 30, 2020.
Ignacio Dominguez, President and CEO of ADAMA, said, “In these unprecedentedly challenging
and concerning times, and despite the widespread constraints on, and changes in, how we do
business all over the world, our Company continues to deliver record business growth, both in the
third quarter and over the nine-month period. However, while global currencies recovered somewhat
against the US Dollar in the third quarter, when compared to the prior year currencies remained
generally weaker, especially in emerging markets where our growth is strongest, which continued to
restrain our sales growth and has severely impacted our profitability in USD terms. Despite this, our
underlying business remains strong, with continued robust business growth and market share gains
in certain key markets, combined with lower procurement costs and reduced operating expenses,
while we remain focused on helping farmers worldwide to do what they do best, feed the world.”
1
Table 1. Financial Performance Summary
% %
Q3 Q3 % FX 9M 9M % FX
Adjusted, USD (m) Change Change
2020 2019 Change Impact 2020 2019 Change Impact
CER CER
Revenues 978 953 +3% -88 +12% 2,987 2,962 +1% -222 +8%
Gross profit 274 295 -7% -75 +18% 869 968 -10% -184 +9%
% of sales 28.0% 31.0% 29.1% 32.7%
Operating income (EBIT) 70 83 -16% -72 +70% 256 325 -21% -164 +29%
% of sales 7.1% 8.7% 8.6% 11.0%
Net income 21 42 -50% -81 +142% 95 173 -45% -201 +71%
% of sales 2.2% 4.4% 3.2% 5.9%
EBITDA 130 144 -10% -71 +40% 436 509 -14% -164 +18%
% of sales 13.3% 15.1% 14.6% 17.2%
EPS
- USD 0.0089 0.0173 -49% 0.0390 0.0708 -45%
- RMB 0.0614 0.1210 -49% 0.2740 0.4836 -43%
CER: Constant Exchange Rates
All income statement items contained in this release are presented on an adjusted basis. The number of shares used to calculate both
basic and diluted earnings per share in 2019 is 2,446.6 million shares. The number of shares used to calculate both basic and diluted
earnings per share in 2020 is 2,423.8 and 2,378.3 million shares for the 9 and 3 month periods, respectively, reflecting the buyback and
cancellation of 102.4 million shares from CNAC in July 2020.
These “Adjusted” results exclude items that are of a one-time or non-cash/non-operational nature
that do not impact the ongoing performance of the business, and reflect the way the Company’s
management and the Board of Directors view the performance of the Company internally. The
Company believes that excluding the effects of these items from its operating results allows
management and investors to effectively compare the true underlying financial performance of its
business from period to period and against its global peers.
A summary of these adjustments and a reconciliation between the Adjusted and Reported financials
appears below:
Q3 Adjusted Adjustments Reported
USD (m) Q3 2020 Q3 2019 Q3 2020 Q3 2019 Q3 2020 Q3 2019
Revenues 978 953 0 0 978 953
Gross profit 274 295 1 0 274 295
Operating income (EBIT) 70 83 20 15 49 68
Income before taxes 23 48 20 15 2 33
Net income 21 42 18 13 3 29
EBITDA 130 144 -7 -8 137 152
Earnings per share 0.0089 0.0173 0.0012 0.1200
2
9M Adjusted Adjustments Reported
USD (m) 9M 2020 9M 2019 9M 2020 9M 2019 9M 2020 9M 2019
Revenues 2,987 2,962 0 0 2,987 2,962
Gross profit 869 968 2 2 867 966
Operating income (EBIT) 256 325 68 66 188 260
Income before taxes 135 204 69 63 66 141
Net income 95 173 63 57 32 116
EBITDA 436 509 -3 -6 438 515
Earnings per share 0.0390 0.0708 0.0131 0.0476
For a detailed description of the above adjustments, please refer to the appendix to this release.
Performance in Context of Market Environment
During the third quarter of 2020, the global agrochemical market is expected to have seen moderate
growth, as the residual impact from COVID-19 continues to linger in many markets. Crop prices
have recovered in many key crops, however, for some such as cotton, planted acreage was lower
due to the lower crop prices at the time of planting during the first half of the year, impacting sales in
this segment in markets such as the US, Brazil and Turkey. Governments across the world continue
to include farmers in extensive support programs, partially offsetting lost income due to the
pandemic.
While global currencies recovered somewhat against the US Dollar during the third quarter, they
generally remained significantly weaker when compared to the third quarter and first nine months of
2019, especially in the emerging markets where the Company is seeing its strongest growth.
Following an extended period of industry-wide supply constraints in recent years due to the
increasingly stringent environmental regulations imposed on Chinese producers, during the first half
of the year, procurement costs of chemical raw materials and intermediates started to decline as
general levels of production and supply increased. This increase in production and supply was seen
despite some disruptions due to the initial COVID-19 outbreak in the first quarter.
The Company started to benefit from this trend in the third quarter as these lower procurement costs
have migrated through the Company’s inventory cycle. However, the lower prices have also had a
negative impact on the Company’s sales of chemical raw materials and intermediates, which form
part of its Ingredients & Intermediates business in both China and Israel.
Acquisition of Huifeng
On October [28], 2020, ADAMA announced the acquisition of a majority stake in a newly established
company that will hold the vast majority of the crop protection synthesis and formulation facilities of
Jiangsu Huifeng Bio Agriculture Co., Ltd (“Huifeng”), a leading Chinese crop protection producer and
key player in the Chinese crop protection market.
Transaction Overview:
Phase I: as announced on November 6, 2019, ADAMA will acquire a 50% stake in Shanghai
Dibai Plant Protection Co., Ltd. (“Dibai”), a wholly-owned subsidiary of Huifeng focused on the
sale and distribution of key formulated crop protection products in China
o Closing of Phase I is expected to occur in the coming weeks, subject to customary approvals
and Closing conditions
Phase II: Under the agreement now executed, ADAMA will further acquire:
3
o a 51% equity stake in Jiangsu Kelinong Co., Ltd. (“Kelinong”), a newly established, wholly-
owned subsidiary of Huifeng to which Huifeng is to transfer its key crop protection synthesis
and formulation facilities;
o an additional 1% in Dibai
Following the completion of these transactions, ADAMA will hold 51% of the equity in both
Kelinong and Dibai, providing ADAMA with a majority stake in one of China’s leading crop
protection manufacturers, and significantly bolstering ADAMA’s commercial presence in the
China crop protection market
The total cash consideration for both phases of the transaction is approximately RMB 1,224
million (approximately $175 million)
Closing of Phase II is subject to customary Closing conditions, including regulatory and other
corporate approvals, and is further subject to full resumption of production at the relevant
facilities of Huifeng. Huifeng has made significant progress in the rectification of its
environmental issues and is in the process of obtaining approvals to resume production activities.
Financial Highlights
Revenues in the third quarter grew by 12% and by 8% in the nine-month period, in CER terms,
compared to the corresponding periods last year. This growth was driven by strong increases in
volumes, up 11% in the quarter and 8% in the nine-month period.
Growth in the quarter was led by a strong performance in Latin America, driven by robust volume
growth across the region despite widespread COVID-19 related restrictions. Continued growth was
also seen in Asia-Pacific as well as in the India, Middle East & Africa region. The noteworthy growth
in the quarter in these regions more than compensated for lower sales in Europe and North America,
largely due to challenging weather conditions.
In US dollar terms, sales grew by a more moderate 3% in the quarter and 1% in the nine-month
period (2% and 3%, respectively in RMB terms), compared to the corresponding periods last year.
The lower growth in USD (and RMB) terms reflects the generally weaker currencies, especially in
the emerging markets of Latin America and the India, Middle East & Africa regions where the
Company is growing the fastest, which constrained sales in US dollar terms by an estimated $88
million and $222 million, respectively, when compared to the same periods last year.
Gross profit in the third quarter was $274 million (gross margin of 28.0%) and $869 million (gross
margin of 29.1%) in the nine-month period, compared to $295 million (gross margin of 31.0%) and
$968 million (gross margin of 32.7%) in the corresponding periods last year, respectively.
The third quarter saw the Company start to benefit from a marked drop in procurement costs which
began earlier in the year and which are now migrating through the Company’s inventory cycle. This
was partially offset by somewhat higher manufacturing costs related to the stronger Israeli shekel.
However, in both the third quarter and nine-month periods, the strong volume growth and lower
procurement costs were more than offset by the material depreciation of global currencies, which
constrained gross profit by an estimated $75 million and $184 million, respectively.
Operating expenses: Total operating expenses in the third quarter were $205 million (20.9% of
sales) and $613 million (20.5% of sales) in the nine-month period, compared to $212 million (22.3%
of sales) and $643 million (21.7% of sales) in the corresponding periods last year, respectively. The
Company continues to maintain tight control of its operating expenses, which were also naturally
constrained by the impact of COVID-19, and saw a marked decrease in expenses in both the
quarter and nine-month periods, despite the inclusion of recent acquisitions. Operating expenses in
the 2020 periods also benefited from the global currency weakness against the US dollar when
4
compared to prior periods, while operating expenses in the 2019 periods were net of income related
to expropriation of land recorded then.
Operating income in the third quarter was $70 million (7.1% of sales) and $256 million (8.6% of
sales) in the nine-month period, compared to $83 million (8.7% of sales) and $325 million (11.0% of
sales) in the corresponding periods last year, respectively. The global currency weakness impacted
operating income by an estimated $71 million in the quarter and $164 million in the nine-month
period.
EBITDA in the quarter was $130 million (13.3% of sales) and $436 million (14.6% of sales) in the
nine-month period, compared to $144 million (15.1% of sales) and $509 million (17.2% of sales)
recorded in the corresponding periods last year, respectively. The global currency weakness
impacted EBITDA in the third quarter by an estimated $71 million and $164 million in the nine-month
period.
Financial expenses and investment income: Total net financial expenses and investment income
were $47 million in the quarter and $121 million in the nine-month period, compared to $35 million
and $122 million in the corresponding periods last year, respectively. The higher financial expenses
in the quarter were due to an increase in financing costs on the NIS-denominated, CPI-linked bonds
due to a higher CPI in Israel, as well as the effect on balance sheet positions of the strengthening of
the RMB when compared to 2019.
Tax expenses: Net tax expenses in the third quarter were $2 million and $41 million in the nine-
month period, compared to $6 million and $30 million in the corresponding periods last year,
respectively. The lower tax expenses in the quarter were driven by the lower operating income,
while the comparative quarter in 2019 saw higher tax expenses due to the devaluation of the
Brazilian Real in that quarter, which resulted in non-cash tax expenses due to differences between
the functional currency (US dollar) and tax currency (BRL) with respect to the value of non-
monetary assets. The higher tax expenses in the nine-month period are largely due to the first-
quarter impact of the weakening of the Brazilian Real against the US dollar, which resulted once
again in an increase in non-cash tax expenses.
Net income in the third quarter was $21 million (2.2% of sales) and $95 million (3.2% of sales) in
the first nine months compared to $42 million (4.4% of sales) and $173 million (5.9% of sales) in the
corresponding periods last year. The Company estimates the net impact of the global currency
headwinds on Net Income to be approximately $81 million in the third quarter and $201 million in the
nine-month period.
Trade working capital at September 30, 2020 was $2,332 million compared to $2,143 million at the
same point last year. The Company is holding somewhat higher inventory levels due to a change in
geographic and portfolio sales mix, as well as due to the anticipation of further volume growth in
coming quarters. The Company also saw an increase in trade receivables, driven largely by its
strong growth over the last year in emerging markets, most notably in Latin America and Brazil,
where customer credit terms are generally longer. These increases were partially offset by higher
trade payables.
Cash Flow: Operating cash flow of $23 million was generated in the quarter and $196 million over
the nine-month period, compared to $57 million and $10 million generated in the corresponding
periods last year, respectively. The lower operating cash flow in the quarter reflects the lower
operating income alongside higher levels of working capital compared to the parallel period last year.
The higher operating cash flow generated in the first nine months of 2020 mainly reflects a more
moderate increase in working capital levels this year than the increase seen in the first nine months
of 2019, which was more significantly affected by the inclusion of the working capital of companies
acquired during that period.
5
Net cash used in investing activities was $84 million in the third quarter and $200 million in the nine-
month period, compared to $42 million and $245 million in the corresponding periods last year,
respectively. The increase in cash used in investing activities in the quarter mainly reflects the
Company’s acquisition in Greece and somewhat higher investment in fixed assets, while the parallel
period in 2019 saw the receipt of proceeds from expropriation of land. Over the nine-month period,
although the Company increased its investment in fixed assets compared to the same period last
year, the overall decrease in cash used in investing activities largely reflects the relatively higher
spend in the same period in 2019 due to the acquisition made in that period.
Free cash flow of $68 million was consumed in the third quarter and $56 million in the nine-month
period compared to $7 million generated and $290 million consumed in the corresponding periods
last year, respectively, reflecting the lower operating cash flow and higher investment spend in the
third quarter of this year, contrasted with the higher working capital build-up and acquisitions seen
over the nine-month period in 2019.
Leverage: Balance sheet net debt at September 30, 2020 was $1,163 million, compared to $960
million at September 30, 2019, reflecting the acquisitions and strong working capital growth seen in
Q4 2019, as well as the free cash flow consumed in the first nine months of this year.
Table 2. Regional Sales Performance
Q3 2020 Q3 2019 Change Change 9M 2020 9M 2019 Change Change
$m $m USD CER $m $m USD CER
Europe 181 188 -4.0% -5.0% 790 816 -3.2% -0.7%
North America 145 160 -9.3% -9.3% 518 560 -7.6% -7.1%
Latin America 335 302 +10.9% +38.7% 714 657 +8.6% +32.7%
Asia Pacific 148 138 +7.0% +5.3% 497 496 0.2% +3.4%
Of which China 82 76 +9.0% +5.0% 250 255 -1.9% -0.9%
India, Middle East & Africa 170 166 +2.8% +7.5% 468 432 +8.3% +14.2%
Total 978 953 +2.6% +11.8% 2,987 2,962 +0.8% +8.4%
CER: Constant Exchange Rates
Europe: Sales were lower by 5.0% in the third quarter and by 0.7% in the nine-month period, in
CER terms, compared with the corresponding periods last year.
The lower sales in the quarter were largely due to the widespread extreme drought conditions which
reduced crop protection application in key crops such as oilseed rape and winter cereals, resulting in
some delayed sales, as well as high inventories in distribution channels. During the quarter, ADAMA
completed the acquisition of the remaining 51% of Alfa in Greece, bolstering its activities in this
important market.
During the quarter, the Company obtained multiple new product registrations in the region, including
COLT, a herbicide for the control of broadleaf weeds in winter cereals and pasture, and FOLPAN
GOLD, a systemic fungicide to combat grapevine mildew, both registered in Bulgaria.
In US dollar terms, sales were lower by 4.0% in the quarter and by 3.2% in the nine-month period,
compared to the corresponding periods last year, reflecting the net impact of the relative
strengthening of European currencies against the US dollar in the quarter, contrasted with their
relative weakness over the nine-month period.
North America: Sales were lower by 9.3% in the third quarter and by 7.1% in the nine-month period,
in CER terms, compared with the corresponding periods last year.
6
Crop protection sales were markedly lower, largely due to disruptive weather conditions in the US
which saw windstorms damage corn fields in the mid-west, fires raging in the orchards and
vineyards of California and Oregon, and a heatwave challenging cotton farmers in Texas already
contending with reduced demand due to the COVID-19 impact on the apparel industry, alongside
low insect pressure impacting sales of insecticides. This was partially mitigated by the robust
performance of the Company’s Consumer and Professional Solutions business, which continues its
strong recovery from the COVID-19 related challenges seen earlier in the year.
The Company continued to expand its differentiated product offering in the region, following the
earlier launches in Canada of CUSTODIA, a combination fungicide controlling a wide range of
diseases in corn, soybeans and wheat, as well as ORIUS, a broad-spectrum fungicide for wheat,
barley and oat crops.
In US dollar terms, sales were lower by 9.3% in the quarter and by 7.6% in the nine-month period,
compared to the corresponding periods last year, reflecting the moderate weakening of the
Canadian Dollar seen in the first half of the year.
Latin America: Sales grew by a robust 38.7% in the third quarter and by 32.7% in the nine-month
period, in CER terms, compared to the corresponding periods last year, driven by significant volume
growth in key countries and continued price increases to partially compensate for the material
weakness of the currencies in the region, and despite widespread COVID-19 related restrictions.
The Company saw significant volume growth in Brazil, driven by strong performances from its
differentiated product portfolio including flagship product CRONNOS, the triple-action fungicide for
soybean rust, GALIL, a differentiated combination insecticide and TRIVOR, a dual-action
insecticide for rapid and extended control of sucking pests, following its successful 2019 launch.
Noteworthy performances were also recorded in Argentina, Colombia, Mexico and Paraguay, as
well as in Peru, bolstered by the Company’s recent acquisition in the country.
On October 14, 2020, ADAMA acquired a majority stake in FNV S.A., its key crop protection
distributor in Paraguay, strengthening the Company’s commercial presence in this important market
and providing ADAMA with direct market access, ensuring the sustainability and growth of its key
distribution platform.
During the quarter, the Company obtained multiple new product registrations in the region, including
ARADDO, a complete solution for the management of a wide range of glyphosate-resistant weeds
in soybean, corn and wheat crops in Brazil.
In US dollar terms, sales in the region grew by 10.9% in the quarter and 8.6% in the nine-month
period, compared to the corresponding periods last year, as the robust business growth was heavily
impacted by weaker currencies in the region, in particular the significant decline in the Brazilian Real
against the US dollar.
Asia-Pacific: Sales grew by 5.3% in the quarter and by 3.4% in the nine-month period, in CER
terms, compared to the corresponding periods last year, driven by continued volume growth.
In Asia-Pacific (outside of China), the Company saw strong performance from Australia and New
Zealand, benefiting from favorable weather, and more than offsetting challenging seasonal
conditions in South East Asia.
During the quarter, the Company obtained multiple new product registrations in the region, including
ULTRO 900 (Carbetamide), a herbicide for the control of grasses in all pulse crops. This is a new
active ingredient in Australia for broadacre cropping, the country’s largest cropping segment.
In China, the Company delivered moderate growth in the quarter, with a strong performance from its
branded, formulated sales being partially offset by lower prices received for its raw materials and
intermediates due to increased supply generally from Chinese producers. The growth in the
7
formulated products was supported by new product launches including AN GUO XUAN, a
protective fungicide for tomatoes, and XIN TUO LONG, an effective growth regulating solution for
cotton harvesting in the Xinjiang region.
In US dollar terms, sales in the region grew by 7.0% in the third quarter but were flat over the nine-
month period, compared to the corresponding periods last year, reflecting the strengthening of the
Chinese Renminbi against the US dollar in Q3, contrasted with the generally weaker currencies over
the nine-month period.
India, Middle East & Africa: Sales grew by 7.5% in the quarter and by 14.2% in the nine-month
period, in CER terms, compared to the corresponding periods last year, driven by robust volume
growth.
The growth in the region was driven mainly by a strong performance in India, which benefited from
above-average monsoon rains and good cropping conditions.
During the quarter, the Company continued to expand its hybrid product offering in the region,
launching TRIGUS, an insecticide for use on sucking pests, in India.
In US dollar terms, sales in the region grew by 2.8% in the quarter and by 8.3% in the nine-month
period, compared to the corresponding periods last year, reflecting the impact of softer currencies,
most notably the Turkish Lira, the Indian Rupee and the South African Rand.
Table 3. Revenues by operating segment
Third quarter sales by segment
Q3 2020 Q3 2019
% %
USD (m) USD (m)
Crop Protection 881 90.0% 855 89.6%
Intermediates and Ingredients 98 10.0% 99 10.4%
Total 978 100.0% 953 100.0%
Third quarter sales by product category
Q3 2020 Q3 2019
% %
USD (m) USD (m)
Herbicides 345 35.2% 375 39.3%
Insecticides 329 33.6% 304 31.8%
Fungicides 207 21.1% 176 18.5%
Intermediates and Ingredients 98 10% 99 10.4%
Total 978 100.0% 1,002 100.0%
Note: the sales split by product category is provided for convenience purposes only and is not representative of the way the Company is
managed or in which it makes its operational decisions.
8
Nine-month sales by segment
9M 2020 9M 2019
% %
USD (m) USD (m)
Crop Protection 2,706 90.6% 2,669 90.1%
Intermediates and Ingredients 280 9.4% 292 9.9%
Total 2,987 100.0% 2,962 100.0%
Nine-month sales by product category
9M 2020 9M 2019
% %
USD (m) USD (m)
Herbicides 1,231 41.2% 1,287 43.5%
Insecticides 859 28.8% 850 28.7%
Fungicides 617 20.6% 532 18.0%
Intermediates and Ingredients 280 9.4% 292 9.9%
Total 2,987 100.0% 2,962 100.0%
Note: the sales split by product category is provided for convenience purposes only and is not representative of the way the Company is
managed or in which it makes its operational decisions.
Further Information
All filings of the Company, together with a presentation of the key financial highlights of the period,
can be accessed through the Company website at www.adama.com.
##
About ADAMA
ADAMA Ltd. is a global leader in crop protection, providing solutions to farmers across the world to
combat weeds, insects and disease. ADAMA has one of the widest and most diverse portfolios of
active ingredients in the world, state-of-the art R&D, manufacturing and formulation facilities,
together with a culture that empowers our people in markets around the world to listen to farmers
and ideate from the field. This uniquely positions ADAMA to offer a vast array of distinctive
mixtures, formulations and high-quality differentiated products, delivering solutions that meet local
farmer and customer needs in over 100 countries globally. For more information, visit us at
www.ADAMA.com and follow us on Twitter at @ADAMAAgri.
Contact
Ben Cohen Zhujun Wang
Global Investor Relations China Investor Relations
Email: ir@adama.com Email: irchina@adama.com
9
Abridged Consolidated Financial Statements
The following abridged consolidated financial statements and notes have been prepared as
described in Note 1. While prepared based on the principles of PRC GAAP, they do not contain all
of the information which either PRC GAAP or IFRS would require for a complete set of financial
statements and should be read in conjunction with the consolidated financial statements of both
ADAMA Ltd. and Adama Agricultural Solutions Ltd. as filed with the Shenzhen and Tel Aviv Stock
Exchanges, respectively.
Abridged Consolidated Income Statement for the Third Quarter
Q3 2020 Q3 2019 Q3 2020 Q3 2019
Adjusted1
USD (m) USD (m) RMB (m) RMB (m)
Revenues 978 953 6,769 6,666
Cost of Sales 701 656 4,849 4,583
Business taxes and surcharges 3 3 21 18
Gross profit 274 295 1,898 2,064
% of revenue 28.0% 31.0% 28.0% 31.0%
Selling & Distribution expenses 155 148 1,071 1,035
General & Administrative expenses 31 32 213 225
Research & Development expenses 13 15 92 108
Other 6 17 39 115
Total operating expenses 205 212 1,416 1,483
% of revenue 20.9% 22.3% 20.9% 22.3%
Operating income (EBIT) 70 83 482 581
% of revenue 7.1% 8.7% 7.1% 8.7%
Financial expenses and investment income 47 35 325 244
Income before taxes 23 48 158 337
Taxes on Income 2 6 11 41
Net income 21 42 146 296
% of revenue 2.2% 4.4% 2.2% 4.4%
EBITDA 130 144 899 1,010
% of revenue 13.3% 15.1% 13.3% 15.1%
Earnings per Share – Basic 0.0089 0.0173 0.0614 0.1210
– Diluted 0.0089 0.0173 0.0614 0.1210
The number of shares used to calculate both basic and diluted earnings per share in 2020 is 2,378.3 million shares,
reflecting the buyback and cancellation of 102.4 million shares from CNAC in July. The number of shares used to calculate
both basic and diluted earnings per share in 2019 is 2,446.6 million shares.
1
For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the
financial statements, see below “Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements”.
10
Abridged Consolidated Income Statement for the First Nine Months
9M 2020 9M 2019 9M 2020 9M 2019
Adjusted2
USD (m) USD (m) RMB (m) RMB (m)
Revenues 2,987 2,962 20,890 20,282
Cost of Sales 2,108 1,984 14,744 13,593
Business taxes and surcharges 10 9 67 65
Gross profit 869 968 6,078 6,624
% of revenue 29.1% 32.7% 29.1% 32.7%
Selling & Distribution expenses 465 472 3,253 3,230
General & Administrative expenses 92 101 640 690
Research & Development expenses 40 46 281 318
Other 16 24 110 164
Total operating expenses 613 643 4,284 4,402
% of revenue 20.5% 21.7% 20.5% 21.7%
Operating income (EBIT) 256 325 1,794 2,222
% of revenue 8.6% 11.0% 8.6% 11.0%
Financial expenses and investment income 121 122 844 833
Income before taxes 135 204 949 1,389
Taxes on Income 41 30 285 206
Net income 95 173 664 1,183
% of revenue 3.2% 5.9% 3.2% 5.9%
EBITDA 436 509 3,048 3,481
% of revenue 14.6% 17.2% 14.6% 17.2%
Earnings per Share – Basic 0.0390 0.0708 0.2740 0.4836
– Diluted 0.0390 0.0708 0.2740 0.4836
The number of shares used to calculate both basic and diluted earnings per share in 2020 is 2,423.8 million shares,
reflecting the buyback and cancellation of 102.4 million shares from CNAC in July. The number of shares used to calculate
both basic and diluted earnings per share in 2019 is 2,446.6 million shares.
2
For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the
financial statements, see below “Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements”.
11
Abridged Consolidated Balance Sheet
September 30 September 30 September 30 September 30
2020 2019 2020 2019
USD (m) USD (m) RMB (m) RMB (m)
Assets
Current assets:
Cash at bank and on hand 842 647 5,733 4,579
Bills and accounts receivable 1,420 1,214 9,668 8,585
Inventories 1,631 1,485 11,110 10,509
Other current assets, receivables and
323 307 2,200 2,171
prepaid expenses
Total current assets 4,216 3,653 28,711 25,844
Non-current assets:
Fixed assets, net 1,152 1,112 7,844 7,866
Rights of use assets 74 78 504 550
Intangible assets, net 1,441 1,447 9,815 10,235
Deferred tax assets 130 111 883 782
Other non-current assets 78 109 535 771
Total non-current assets 2,875 2,857 19,581 20,203
Total assets 7,091 6,510 48,293 46,047
Liabilities
Current liabilities:
Loans and credit from banks and
487 298 3,314 2,106
other lenders
Bills and accounts payable 739 581 5,032 4,109
Other current liabilities 782 707 5,326 5,002
Total current liabilities 2,008 1,586 13,672 11,218
Long-term liabilities:
Loans and credit from banks and
319 141 2,169 998
other lenders
Debentures 1,234 1,206 8,402 8,533
Deferred tax liabilities 57 52 387 368
Employee benefits 102 102 693 719
Other long-term liabilities 147 140 1,004 989
Total long-term liabilities 1,859 1,641 12,657 11,607
Total liabilities 3,866 3,227 26,329 22,825
Equity
Total equity 3,225 3,283 21,964 23,222
Total liabilities and equity 7,091 6,510 48,293 46,047
12
Abridged Consolidated Cash Flow Statement for the Third Quarter
Q3 2020 Q3 2019 Q3 2020 Q3 2019
USD (m) USD (m) RMB (m) RMB (m)
Cash flow from operating activities:
Cash flow from operating activities 23 57 157 399
Cash flow from operating activities 23 57 399
157
Investing activities:
Acquisitions of fixed and intangible assets -72 -69 -498 -484
Proceeds from disposal of fixed and intangible assets 0 26 -3 151
Acquisition of subsidiaries -14 0 -96 -
Other investing activities 2 1 18 41
Cash flow used for investing activities -84 -42 -579 -292
Financing activities:
Receipt of loans from banks and other lenders 149 97 1,030 680
Repayment of loans from banks and other lenders -134 -146 -926 -1,020
Interest payment and other -7 -9 -50 -64
Dividend to shareholders -1 -35 -5 -237
Acquisition via combination under common control - -59 - -415
Other financing activities 0 6 0 36
Cash flow from (used for) financing activities 7 -146 49 -1,020
Effects of exchange rate movement on cash and cash
6 -8 -189 87
equivalents
Net change in cash and cash equivalents -48 -139 -562 -827
Cash and cash equivalents at the beginning of the period 884 783 6,256 5,382
Cash and cash equivalents at the end of the period 836 644 5,694 4,555
Free Cash Flow -68 7 -471 44
13
Abridged Consolidated Cash Flow Statement for the First Nine Months
9M 2020 9M 2019 9M 2020 9M 2019
USD (m) USD (m) RMB (m) RMB (m)
Cash flow from operating activities:
Cash flow from operating activities 196 10 1,392 94
Cash flow from operating activities 196 10 1,392 94
Investing activities:
Acquisitions of fixed and intangible assets -186 -158 -1,301 -1,090
Proceeds from disposal of fixed and intangible assets 3 26 18 182
Acquisition of subsidiaries -14 -123 -96 -827
Other investing activities -3 10 -15 73
Cash flow used for investing activities -200 -245 -1,394 -1,662
Financing activities:
Receipt of loans from banks and other lenders 550 391 3,852 2,668
Repayment of loans from banks and other lenders -240 -214 -1,672 -1,484
Interest payments and other -57 -60 -400 -413
Dividend to shareholders -2 -43 -11 -294
Acquisition via combination under common control - -59 - -415
Other financing activities -34 -52 -245 -347
Cash flow from (used for) financing activities 217 -37 1,524 -285
Effects of exchange rate movement on cash and cash
4 -9 -148 62
equivalents
Net change in cash and cash equivalents 217 -281 1,374 -1,791
Cash and cash equivalents at the beginning of the period 619 925 4,320 6,346
Cash and cash equivalents at the end of the period 836 644 5,694 4,555
Free Cash Flow -56 -290 -376 -1,952
14
Notes to Abridged Consolidated Financial Statements
Note 1: Basis of preparation
Basis of presentation and accounting policies: The abridged consolidated financial statements for the
quarters ended September 30, 2020 and 2019 incorporate the financial statements of ADAMA Ltd. and of all
of its subsidiaries (the “Company”), including Adama Agricultural Solutions Ltd. (“Solutions”) and its
subsidiaries.
The Company has adopted the Accounting Standards for Business Enterprises issued by the Ministry of
Finance (the "MoF") and the implementation guidance, interpretations and other relevant provisions issued or
revised subsequently by the MoF (collectively referred to as "CASBE").
The abridged consolidated financial statements contained in this release are presented in both Chinese
Renminbi (RMB), as the Company’s shares are traded on the Shenzhen Stock Exchange, as well as in United
States dollars ($) as this is the major currency in which the Company’s business is conducted. For the
purposes of this release, a customary convenience translation has been used for the translation from RMB to
US dollars, with Income Statement and Cash Flow items being translated using the quarterly average
exchange rate, and Balance Sheet items being translated using the exchange rate at the end of the period.
The preparation of financial statements requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements, and the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimated.
Note 2: Abridged Financial Statements
For ease of use, the Financial Statements shown in this release have been abridged as follows:
Abridged Consolidated Income Statement:
“Operating expenses” includes selling and distribution expenses; general and administrative expenses;
research and development expenses; impairment losses; gain (loss) from disposal of assets and non-
operating income and expenses
“Financial expenses and investment income” includes net financing expenses; gains from changes in
fair value; and investment income (including share of income of equity accounted investees)
Abridged Consolidated Balance Sheet:
“Other current assets, receivables and prepaid expenses” includes financial assets held for trading;
financial assets in respect of derivatives; prepayments; other receivables; and other current assets
“Fixed assets, net” includes fixed assets and construction in progress
“Intangible assets, net” includes intangible assets and goodwill
“Other non-current assets” includes other equity investments; long-term equity investments; long-term
receivables; investment property; and other non-current assets
“Loans and credit from banks and other lenders” includes short-term loans and non-current liabilities
due within one year
“Other current liabilities” includes financial liabilities in respect of derivatives; payables for employee
benefits, taxes, interest, dividends and others; advances from customers and other current liabilities
“Other long-term liabilities” includes long-term payables, provisions, deferred income and other non-
current liabilities
15
Analysis of Gaps between Adjusted Income Statement and Reported
Income Statement in Financial Statements
For the below tables in USD terms, please see page 2 of this release.
Q3 Adjusted Adjustments Reported
Q3
RMB(m) Q3 2020 Q3 2019 Q3 2019 Q3 2020 Q3 2019
2020
Revenues 6,769 6,666 0 0 6,769 6,666
Gross profit 1,898 2,064 4 1 1,894 2,063
Operating expenses 1,416 1,483 -137 -103 1,553 1,586
Operating income (EBIT) 482 581 141 104 341 477
Income before taxes 158 337 141 104 17 233
Net income 146 296 126 90 20 206
EBITDA 899 1,010 -50 -54 950 1,064
Earnings per share 0.0614 0.1210 0.0086 0.0842
9M Adjusted Adjustments Reported
9M
RMB(m) 9M 2020 9M 2019 9M 2019 9M 2020 9M 2019
2020
Revenues 20,890 20,282 0 0 20,890 20,282
Gross profit 6,078 6,624 13 14 6,065 6,610
Operating expenses 4,284 4,402 -465 -433 4,749 4,835
Operating income (EBIT) 1,794 2,222 478 448 1,315 1,775
Income before taxes 949 1,389 484 427 466 962
Net income 664 1,183 439 388 225 795
EBITDA 3,048 3,481 -21 -43 3,069 3,524
Earnings per share 0.2740 0.4836 0.0929 0.3248
16
Income Statement Adjustments
Q3 2020 Q3 2019 Q3 2020 Q3 2019
USD (m) USD (m) RMB (m) RMB (m)
Net Income (Reported) 3.0 29.5 20.4 206.1
Adjustments to COGS & Operating Expenses:
1. Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash) 11.5 11.5 79.2 80.1
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-
7.6 7.7 52.5 53.5
Syngenta transaction (non-cash)
3. China Relocation & Upgrade related costs 0.6 1.6 4.3 11.2
4. Long-term incentive (non-cash) -2.5 -7.8 -17.6 -54.3
5. Amortization of acquisition-related PPA (non-cash) 2.2 1.9 14.9 13.4
6. Employee early retirement expenses 0.6 - 3.8 -
7. Capital gain recognized on acquisition of control of an equity investee -8.5 - -59.0 -
8. Non-core assets impairment 9.0 - 62.6 -
Total Adjustments to Operating Income (EBIT) 20.4 14.9 140.8 103.9
Total Adjustments to EBITDA -7.3 -7.7 -50.2 -53.7
Total Adjustments to Income before Taxes 20.4 14.9 140.8 103.9
Adjustments to Taxes
1. Tax shield on Legacy PPA of 2011 acquisition of Solutions 1.9 1.9 13.5 13.6
5. Deferred tax due to PPA 0.2 0.1 1.7 0.5
Total adjustments to Net Income 18.2 12.8 125.7 89.8
Net Income (Adjusted) 21.1 42.3 146.1 296.0
9M 2020 9M 2019 9M 2020 9M 2019
USD (m) USD (m) RMB (m) RMB (m)
Net Income (Reported) 31.8 116.4 222.1 497.4
Adjustments to COGS & Operating Expenses:
1. Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash) 34.4 34.4 239.6 235.4
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-
23.0 27.5 160.3 187.7
Syngenta transaction (non-cash)
3. China Relocation & Upgrade related costs 2.4 6.1 17.1 41.9
4. Long-term incentive (non-cash) -7.7 -6.4 -54.4 -45.0
5. Amortization of acquisition-related PPA (non-cash) 5.8 4.0 41.9 27.5
6. Employee early retirement expenses 10.0 - 70.0 -
7. Capital gain recognized on acquisition of control of an equity investee -8.5 - -59.0 -
8. Non-core assets impairment 9.0 - 62.6 -
Total Adjustments to Operating Income (EBIT) 68.5 65.6 478.2 447.5
Total Adjustments to EBITDA -3.0 -6.1 -20.8 -43.4
Adjustments to Financing Expenses:
9. Revaluation of non-cash adjustment related to non-controlling interest 0.8 -3.0 5.6 -20.5
Total Adjustments to Income before Taxes 69.3 62.5 483.9 427.0
Adjustments to Taxes
1. Tax shield on Legacy PPA of 2011 acquisition of Solutions 5.8 5.8 40.7 40.0
5. Deferred tax due to PPA 0.6 -0.2 4.1 -1.4
Total adjustments to Net Income 62.9 56.9 439.0 388.3
Net Income (Adjusted) 94.6 173.3 664.1 1,183.1
17
Notes:
1. Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash): Under PRC GAAP, the Company has inherited the historical
“legacy” amortization charge from the first combined reporting for Q3 2017 that ChemChina previously was incurring in respect of its acquisition
of Solutions in 2011. This amortization is done in a linear manner on a quarterly basis, most of which will be completed and removed in the
second half of 2020.
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash): The proceeds from
the Divestment of crop protection products in connection with the approval by the EU Commission of the acquisition of Syngenta by
ChemChina, net of taxes and transaction expenses, were paid to Syngenta in return for the transfer of a portfolio of products in Europe of
similar nature and economic value. Since the products acquired from Syngenta are of the same nature and with the same net economic value
as those divested, and since in 2018 the Company excluded the one-time gain that it made on the divested products, the additional
amortization charge incurred due to the written-up value of the acquired assets is also excluded to present a consistent view of Divestment and
Transfer transactions, which had no net impact on the underlying economic performance of the Company. These additional amortization
charges will continue until 2032 but at a reducing rate, yet will still be at a meaningful level (more than $10 million per year) until 2028.
3. China Relocation & Upgrade related costs: These are non-cash accelerated depreciation charges related to the three-year Relocation &
Upgrade program in China. Production assets located in the old production sites in Jingzhou and Huai’An will be relocated to the new sites in
the coming years. Since some of the older production assets may not be able to be relocated, their economic life has been shortened and
therefore will be depreciated over a shorter period. Since these are older assets that were built many years ago and will be replaced by newer
production facilities at the new sites, and since the ongoing operations of the business will not be impacted thereby, the Company adjusts for
the impact of the accelerated depreciation of these assets.
4. Long-term Incentive (non-cash): The Company granted its employees, who are mainly non-Chinese residents, a long-term incentive (LTI) in
the form of 'phantom' options, due to the complexity of granting Chinese-listed, equity-settled options to non-Chinese employees. As such, the
Company records an expense, or recognizes income, depending on the fluctuation in the Company’s share price, even though the Company
will not incur any cash impact prior to exercise of the phantom options. To neutralize the impact of such share price movements on the
measurement of the Company’s performance and expected employee compensation and to reflect the existing phantom options, in the
Company’s adjusted financial performance, the LTI is presented on an equity-settled basis in accordance with the value of the existing plan at
the grant date.
5. Amortization of acquisition-related PPA (non-cash): Related to the amortization of non-cash intangible assets created as part of the
allocation of the purchase price (PPA) on acquisitions; has no impact on the ongoing performance of the companies acquired.
6. Employee early retirement expenses: Provision for early retirement plan of employees at the Company’s Israeli manufacturing sites
7. Capital gain recognized on acquisition of control of an equity investee: On 1 July 2020, ADAMA acquired the remaining 51% stake in Alfa
Agricultural Supplies, S.A., and in so doing, gained control over the company which previously was accounted for as an equity investee. As a
result of the change of consolidation scope, the company recognized a one-time, non-cash, capital gain.
8. Non-core assets impairment: One-time, non-cash charge due to impairment of peripheral, non-material assets.
9. Revaluation of non-cash adjustment related to non-controlling interest: Relates to put options issued to non-controlling interests as part
of historical business combinations which took place before January 1, 2010. The put options are presented as a liability at the present value of
the future exercise price. The revaluation of these put options in Solutions is recognized under IFRS to Goodwill, but due to the acquisition of
Solutions by the Company in 2017, which is treated from an accounting perspective as a “Business Combination Under Common Control”,
such revaluation is recorded as a profit or loss item in the financial reports of the Company. The revaluations of such put options have no
bearing on the ongoing performance of the Company and are therefore adjusted for.
18
Exchange Rates of the Company's Principal Functional Currencies
September 30 Q3 Average 9M Average
2020 2019 Change 2020 2019 Change 2020 2019 Change
EUR/USD 1.170 1.093 7.1% 1.169 1.112 5.1% 1.123 1.124 (0.1%)
USD/BRL 5.641 4.164 (35.5%) 5.380 3.974 (35.4%) 5.076 3.888 30.6%
USD/PLN 3.866 4.000 3.4% 4.096 3.885 (5.4%) 3.939 3.829 (2.9%)
USD/ZAR 16.920 15.083 (12.2%) 17.976 14.677 (22.5%) 16.747 14.367 (16.6%)
AUD/USD 0.712 0.676 5.2% 0.655 0.686 (4.5%) 0.675 0.699 (3.5%)
GBP/USD 1.282 1.229 4.3% 1.241 1.232 0.7% 1.270 1.273 (0.2%)
USD/ILS 3.441 3.482 1.2% 3.516 3.527 0.3% 3.477 3.589 3.1%
USD LIBOR 3M 0.23% 2.09% (88.8%) 0.25% 2.20% (88.5%) 0.80% 2.46% (67.6%)
September 30 Q3 Average 9M Average
2020 2019 Change 2020 2019 Change 2020 2019 Change
USD/RMB 6.810 7.073 (3.7%) 6.919 6.992 (1.0%) 6.993 6.851 2.1%
EUR/RMB 7.967 7.729 3.1% 8.086 7.774 4.0% 7.850 7.699 2.0%
RMB/BRL 0.828 0.589 (40.7%) 0.778 0.568 (36.8%) 0.726 0.567 (27.9%)
RMB/PLN 0.568 0.566 (0.4%) 0.549 0.556 1.1% 0.563 0.559 (0.8%)
RMB/ZAR 2.485 2.133 (16.5%) 2.444 2.099 (16.4%) 2.395 2.097 (14.2%)
AUD/RMB 4.845 4.783 1.3% 4.948 4.793 3.2% 4.718 4.791 (1.5%)
GBP/RMB 8.729 8.694 0.4% 8.935 8.615 3.7% 8.883 8.718 1.9%
RMB/ILS 0.492 0.492 0.0% 0.494 0.504 2.1% 0.497 0.524 5.1%
19
